Background: Epstein-Barr virus infection, smoking, HLA-A*02, and DRB1*15 have all been proposed as risk factors for multiple sclerosis (MS). In 2010, Simon et al. described an interaction on the multiplicative scale between EBNA1 immunoglobulin G (IgG) and smoking regarding risk of MS, a finding that we attempted to replicate.
Multiple sclerosis (MS) is considered to be a complex disease where genetic and environmental factors interact to influence disease susceptibility. The strongest genetic factors determining MS risk are the 2 human leukocyte antigen (HLA) alleles, DRB1*15 and A*02. 1 Among environmental risk factors for MS, Epstein-Barr virus (EBV), vitamin D levels, and cigarette smoking are the most studied. 2 Recently results on statistical interactions between HLA-DRB1*15, EBNA1 immunoglobulin G (IgG) titers, and smoking (ever/never smokers) regarding the risk of MS were published. 3 Our aim was to establish if we could replicate their findings in a Swedish case-control study known as the Epidemiologic Investigations in Multiple Sclerosis study (EIMS) , and also to study interactions between these risk factors on the additive scale using departure of additivity as criterion, estimated as attributable proportion (AP, the proportion of the cases attributable to the interaction per se) due to interaction with a 95% confidence interval (CI). 4 METHODS The general design 5 of the EIMS study and methods 6 which this article is based upon have been described previously. The study population includes patients with newly diagnosed MS and population-based matched controls (matched for age, sex, and area of residence) recruited from more than 30 clinics from all over Sweden. When a patient is included in the study, 2 controls are randomly chosen from the population, matched to the patients on gender, area of residence, and date of birth (5-year intervals). For each patient, we use the age at index. For controls, age at index is how old each control was at the index date for the matched patient. All participants are asked to answer an extensive questionnaire regarding lifestyle and previous infections. Not all controls answered the questionnaire or left a blood sample, leaving many cases without any matched control. Often the blood sample from the control is also received later than that of the corresponding case. For some variables, like EBNA1 IgG, we analyzed all samples available in June 2008. Many control samples that were later collected and genotyped were not included in the EBNA1 IgG ELISA run. We concluded that we lose a lot of power in a conditional analysis, since around 30% of both cases and controls are lost in the conditional analysis. The study was approved by the Ethical Review Board at Karolinska Institutet and all participants provided written informed consent.
HLA genotyping was performed using Olerup HLA lowresolution kits (Qiagen, Hilden, Germany), according to the manufacturer's protocol. EBNA1 IgG levels were measured with ELISA (Biotest, Dreieich, Germany). Association to MS risk was calculated using unconditional logistic regression with adjustment for the matching factors. Interaction on the multiplicative scale was calculated by adding a multiplicative term to the logistic regression model. Interaction on the additive scale, as measured by attributable proportion due to interaction, was assessed using a modified version of a published script, 7 in R (version 2.12.2) (script available upon request). Conditional logistic regression was performed using the clogit command in R. p Values less than 0.05 were considered significant. For 552 cases and 625 controls, we had EBNA1 IgG titer measurement, HLA-A*02 and DRB1*15 genotypes, and smoking status (never/ever). For 662 MS cases and 848 controls, we had information from the questionnaire regarding infectious mononucleosis infection (yes/ no), HLA-A*02 and DRB1*15 genotypes, and smoking status (never/ever). All included cases fulfill the McDonald criteria for MS and all participants included in this study were of Scandinavian ancestry. RESULTS EBNA1 IgG titers were associated with an increased risk of MS (odds ratio [OR] ϭ 1.79, 95% CI 1.42-2.27) when classified as above or below the median among controls. 6 The presence of DRB1*15 and A*02 were both associated to MS, DRB1*15, OR ϭ 3.24 (95% CI 2.54 -4.13), and A*02, OR ϭ 0.56 (95% CI 0.44 -0.71). Ever smoking was associated with MS risk, OR ϭ 1.30 (95% CI 1.03-1.64, p ϭ 0.03) (table 1). Infectious mononucleosis positivity was also associated with MS, OR ϭ 1.96 (95% CI 1.44 -2.68, p ϭ 3 ϫ 10 Ϫ5 ).
Unlike the recently published study, we did not observe any interaction on the multiplicative scale between EBNA1 IgG or infectious mononucleosis and smoking with regard to MS risk (table 2 and table e-1 on the Neurology ® Web site at www.neurology.org). The strength of association between EBNA1 IgG titer and MS was comparable between never smokers and ever smokers, OR ϭ 1.97 (95% CI 1.39 -2.80) and OR ϭ 1.61 (95% CI 1.16 -2.23), respectively. In comparison, Simon et al. 3 reported a significantly higher association between EBNA1 IgG and MS among ever smokers compared to that among never smokers. We observed no interaction between EBNA1 IgG and DRB1*15 on the multiplicative scale (table 2) .
However, we did observe interactions on the additive scale between EBNA1 IgG and DRB1*15 (AP ϭ 0.34, 95% CI 0.11-0.57, p ϭ 5 ϫ 10 Ϫ3 ), and between EBNA1 IgG and absence of A*02 (AP ϭ 0.36, 95% CI 0.13-0.59, p ϭ 2 ϫ 10 Ϫ3 ). Similar but less significant interactions were observed for infectious mononucleosis (table e-1).
In the conditional logistic regression, many of our findings were not significant, especially in smaller subgroups, likely due to lack of power (tables e-1, e-2, and e-3).
We also performed a risk group analysis of different combinations of the 4 risk factors (figure). Indi- 3 We used 2 methods to determine the interaction between the factors, logistic regression to assess interaction on the multiplicative scale, and AP due to interaction to assess interaction on the additive scale, in 552 cases and 625 controls. We also had access to HLA-A*02 genotypes and did the same type of analysis for A*02. DISCUSSION Increase in EBNA1 IgG titers is a well-known risk factor for MS, which we have also seen in this dataset. We have previously published data indicating that titers of IgG antibodies directed toward the 385-420 aa fragment of EBNA1 were more strongly associated with MS than EBNA1 IgG titers. We observed an interaction on the additive scale between antibodies direct toward the 385-420 aa fragment of EBNA1 IgG and DRB1*15, as well as an interaction between antibodies direct toward the 385-420 aa fragment of EBNA1 IgG and absence of A*02. 6 The results shown here, with interactions on the additive scale between EBNA1 IgG titers and DRB1*15, and EBNA1 IgG and absence of A*02 are Risk group analysis with the 4 risk factors for multiple sclerosis (MS) included in this study, smoking, DRB1*15 and absence of HLA-A*02, and anti-EBNA antibody status. The data were stratified as described in the table below, smoking was ever vs never smokers. Association to MS was measured as odds ratio, with 95% confidence intervals, and p value (p values Ͼ0.05 were considered significant). IgG ϭ immunoglobulin G.
consistent with our previous findings. Many findings were not statistically significant in the conditional logistic regression analysis. The propensity to donate blood was lower among controls, leaving many cases without any matched control (or only 1 control), which led to a loss of power in the conditional analysis. We have also published data indicating an interaction between smoking (current vs nonsmokers) and DRB1*15, which was especially strong among A*02 negative individuals. 8 It is therefore likely that a better understanding of the interplay between different risk factors may shed light on the pathogenesis of MS. In this study, we could not confirm an interaction between EBNA1 IgG and cigarette smoking on MS risk, which was reported previously by Simon et al. 3 Recently, Riise and colleagues (ECTRIMS abstract, 2011) showed a negative interaction between smoking and infectious mononucleosis (as a proxy for EBV infection) on the multiplicative scale. We did not see any interaction on either the multiplicative or the additive scale between smoking and infectious mononucleosis and cannot confirm their results in our study.
The discrepancy between results from this study and that of Simon et al. could be explained by differences in study design. The Simon et al. study pooled data from 3 different studies. The Nurse's Health Study is a cohort study, with blood sampling performed mostly after disease onset. Smoking information was taken from the questionnaire closest in time to sampling. In contrast, the Tasmanian material consists of prevalent cases with smoking habits assessed through nurse-administered interviews, and blood collected at the same time. Swedish case and control samples were mostly drawn after disease onset and smoking data were obtained from questionnaires made at the time of blood draw.
In terms of percent smokers (ever/never) and HLA-DRB1*15 positivity the EIMS study is similar to the data presented in the Simon et al. article. However, the EIMS participants are younger, mean age 34.3 years for cases and 35.8 for controls, compared to 49.3 years for cases and controls in the Simon et al. study. This may increase the risk for recall bias in reporting smoking history, due to older age, and especially among cases due to reduced cognitive function as a consequence of the disease. It also implies longer disease duration and more disabled cases, which could influence the anti-EBV response. Similarly to Simon et al., we only have EBNA1 IgG measurement from one time point, and cannot account for any changes in serology over time.
The EIMS study has a participation rate of 93% among cases and 73% among controls 5 and the existence of nonresponders may introduce selection bias. There is also a risk of recall bias in the self-reported smoking status leading to misclassification of exposure. However, the frequency of smoking in the controls is similar to those observed in the general population. The power in the EIMS study (n ϭ 1,177; 552 cases and 625 controls) is comparable to the 3 other studies combined in the Simon et al. article (n ϭ 1,362; 450 cases and 912 controls). 3 The 3 studies are from different parts of the world, and participants were collected at different time points and in different manners, increasing the risk for differences in exposure and exposure misclassification. In EIMS, data and blood sample are collected shortly after diagnosis in the same manner for all participants. However, the time from onset to diagnosis is, on average, 3.8 years, 5 making it possible that there is also some bias in exposure measurement in the EIMS study. Since the EIMS study includes newly diagnosed cases, comparatively shortly after disease onset, from a fairly homogenous population, we are inclined to believe our results are a more accurate representation of biological processes involved in disease development.
The exact mechanisms through which smoking and EBV infection cause MS are not known. For EBV, molecular mimicry is one possibility, as there are sequence similarities between EBNA1 and myelin basic protein, 9 and between EBNA1 and ␣␤crystallin, an inflammation inhibitor. 10 In the lungs of smokers there is an increased activation of T cells. 11 There is also increased post-translational modification of proteins, 12 which could render them more autoantigenic 13 or cross-reactive with CNS peptides. It is also possible that smoking and EBV independently can promote a state of chronic immune response, in which HLA has a key role, mediating disease development.
